News
12.07.2023
World Orphan Drug Alliance (WODA) Marks their First Anniversary
04.05.2023
EffRx Attends the WCO IOF-ESCEO Congress
EffRx Pharmaceuticals is attending the WCO IOF-ESCEO – World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases – which will take place from May 4 -7, 2023 in Barcelona, Spain.
The IOF Congress is one of the most significant events in the field of osteoporosis and bone health, bringing together renowned scientists, healthcare professionals, and industry experts from around the world.
21.02.2023
EffRx Supports the 16th Annual Rare Disease Day on 28. February 2023
Rare Disease Day is the official international awareness-raising campaign for rare diseases. Rare Disease Day takes place on the last day of February each year. The main objective of the campaign is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients’ lives.
Rare Disease Day was launched by EURORDIS –Rare Diseases Europe and its Council of National Alliances in 2008. On and around this day, hundreds of patient organizations from countries and regions all over the world will hold awareness-raising activities.
The statistics speak for themselves: more than 300 million patients, families and carers make up the rare disease community worldwide with Over 6,000 different diseases.
EffRx supports Eurordis, the organizer of Rare Disease Day, in making the voice of rare diseases heard.
To get involved, visit rarediseaseday.org to find an event near you or to download communication materials.
24.01.2023
EffRx Attending the Annual Meeting SSEDP / SGPED on 26. January 2023 at the Universitäts-Kinderspital Zürich
The Swiss Society for Pediatric Endocrinology and Diabetology (SGPED) is composed of pediatric endocrinologists and individuals from allied health professions. Together with supporting sponsors like EffRx, the Society is jointly committed to improving the care of children and adolescents with endocrinological diseases and diabetes mellitus. For the second year in a row, EffRx will be present at the annual meeting of SGPED, taking place this year in Zürich.
20.12.2022
EffRx Attends the 1st Eastern Switzerland Symposium on Rare Diseases in St. Gallen, Switzerland
The Eastern Switzerland Symposium of Rare Diseases took place for the first time on November 24, 2022 and attracted a high number of participants from a broad range of disciplines. The motto of the conference, chaired by experts from the Cantonal Hospital St. Gallen and Eastern Switzerland Children’s Hospital, was “Learning from the Rare Diseases for the Common Ones”. The symposium offered the opportunity to learn more about rare diseases from competent speakers and engage in productive discussions. Having the patient perspective in mind, exchanges focused on recent and future development of diagnostics and patient care in patients with rare diseases
13.07.2022
EffRx Attending the 9th I-DSD Symposium 2022 in Bern, Switzerland, University Hospital Bern from 14-16th July 2022
The International Symposium on the Differences & Disorders of Sex Development I-DSD has been very successful in attracting a rapidly expanding multidisciplinary group of experts, eager to discuss the latest advances in the field and have laid the foundation for fruitful international collaborations.
In 2021, the I-DSD/I-CAH/I-TS has a network that reaches 260 centers in 63 countries on all continents. Of these, 115 centers from 40 countries use the registries and have entered over 5,500 cases where information can be shared for a range of purposes that have the ultimate aim of improving the health of people with these rare conditions.
06.07.2022
EffRx Featured as Member of WODA in Rare Revolution Magazine
“World Orphan Drug Alliance (WODA): bringing therapies to underserved patients around the globe.”
07.04.2022
EffRx Exhibiting at the Austrian-Swiss Metabolic Meeting in Zürich on the 7th and 8th of April 2022
EffRx is having a booth at the ASMM 2022 Meeting which focuses on “New technologies, new treatments and new challenges.” EffRx will present two products, the Swiss-marketed Miglustat and soon-to-be-launched Alkindi.
23.02.2022
EffRx Supports the 15th Annual Rare Disease Day on 28. February 2022
Rare Disease Day is the globally-coordinated movement on rare diseases, working towards equity in social opportunity, healthcare, and access to diagnosis and therapies for people living with a rare disease.
Since its creation in 2008, Rare Disease Day has played a critical part in building an international rare disease community that is multi-disease, global, and diverse– but united in purpose.
Rare Disease Day is observed every year on 28 February (or 29 in leap years)—the rarest day of the year.
Rare Disease Day was set up and is coordinated by EURORDIS and 65+ national alliance patient organisation partners. Rare Disease Day provides an energy and focal point that enables rare diseases advocacy work to progress on the local, national and international levels.
To learn more visit rarediseaseday.org
20.01.2022
EffRx Attending the Annual Meeting SSEDP / SGPED on 20. January 2022 in St. Gallen
The Swiss Society for Pediatric Endocrinology and Diabetology (SGPED) is composed of pediatric endocrinologists and individuals from allied health professions. EffRx, a sponsor of SGPED, is jointly committed to improving the care of children and adolescents with endocrinological diseases and diabetes mellitus.
09.06.2021
EffRx Seeks New Business Collaborations at the BIO International Convention Digital 2021
At the BIO International Convention Digital, taking place June 10-11 & 14-18, 2021, EffRx pro-actively seeks in-licensing opportunities for Europe in niche therapeutic areas, with a primary interest for rare diseases. Registered companies can still meet with EffRx in virtual BIO One-On-One Partnering meetings. Please contact us via the partnering platform or at info@effrx.com.
BIO is the world’s largest advocacy association representing member companies, state biotechnology groups, academic and research institutions, and related organizations across the United States and in 30+ countries.
25.05.2021
Dr. Nathalie Véron Appointed Director Technical Operations & Qualified Person at EffRx Pharmaceuticals
FREIENBACH, Switzerland, May 2021 – EffRx Pharmaceuticals SA is pleased to announce the appointment of Dr. Nathalie Véron as Director Technical Operations & Qualified Person. She is responsible for overseeing all technical operations activities at EffRx, such as manufacturing relations, supply chain and quality management.
Prior to joining EffRx, Dr. Véron has held various local and global, cross-functional leadership positions in Manufacturing Science and Technology at F. Hoffmann-La Roche, Technical Operations. In addition, she significantly contributed to Digital Supply Chain and Quality Transformation projects in the pharmaceutical industry.
Dr. Véron is a pharmacist by education, who graduated from the University of Freiburg, Germany. She holds a PhD in Biology from the Free University Berlin, Germany and has over 10 years of experience as a Biomedical Scientist.
“We are excited to have such an experienced and dynamic person joining our diverse team,” said Mr. Lorenzo Bosisio, CEO of EffRx Pharmaceuticals. “Nathalie’s capabilities will play an important role in the direct commercialization of niche and orphan medicines by EffRx as well as to further advance our operational standards.”
Dr. Véron commented, “I am excited to contribute to the growth and value creation of this dynamic, innovative company, given the smart and passionate people in the Company and its expanding portfolio of products for new and orphan therapeutic areas. I believe that the company’s approach to deliver innovative, high quality products allows us to make a difference for the patients.”
About EffRx Pharmaceuticals
EffRx Pharmaceuticals is a commercial-stage pharmaceutical company focused on the late stage development and commercialization of prescription medications for niche and orphan indications. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients.
EffRx pro-actively seeks in-licensing opportunities for Europe in niche therapeutic areas, with a primary interest for rare diseases, where EffRx has received an orphan drug designation (ODD) from the FDA for a pipeline asset.
EffRx’s go-to-market competence is proven by the development, launch and lucrative expansion of Binosto® in a highly competitive European market. Our lead commercialized product, Binosto® for the treatment of osteoporosis, is marketed in the US as well as selected European and Asian countries.
15.02.2021
EffRx Pharmaceuticals Announces the Release of Binosto® Data in Two Publications
FREIENBACH, Switzerland – EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced the publication of new scientific data on its Binosto® (buffered soluble alendronate). The data appeared in two major medical journals.1,2
The findings from the study “A novel effervescent formulation of oral weekly alendronate (70 mg) improves persistence compared to alendronate tablets in post‑menopausal women with osteoporosis” demonstrate that Binosto® can provide greater persistence and improved tolerability compared to alendronate tablets, allowing it to be a viable alternative option in the management of osteoporosis.
The article “Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy” provides an economic analysis which indicates that Binosto® may represent a cost-effective strategy compared with relevant alternative treatments for the treatment of postmenopausal women with osteoporosis in Italy aged 60 years and over.
Both publications can be found at: https://doi.org/10.1007/s40520-020-01777-9 and https://doi.org/10.1007/s00198-020-05802-5
- Giusti, A., Bianchi, G., Barone, A. et al. A novel effervescent formulation of oral weekly alendronate (70 mg) improves persistence compared to alendronate tablets in post-menopausal women with osteoporosis. Aging Clin Exp Res (2021). https://doi.org/10.1007/s40520-020-01777-9
- Hiligsmann, M., Maggi, S., Veronese, N. et al. Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy. Osteoporos Int (2021). https://doi.org/10.1007/s00198-020-05802-5
About EffRx Pharmaceuticals
EffRx Pharmaceuticals is a commercial-stage pharmaceutical company focused on the late stage development and commercialization of prescription medications for niche and orphan indications. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients.
EffRx pro-actively seeks in-licensing opportunities for Europe in niche therapeutic areas, with a primary interest for rare diseases, where EffRx has received an orphan drug designation (ODD) from the FDA for a pipeline asset.
EffRx’s go-to-market competence is proven by the development, launch and lucrative expansion of Binosto® in a highly competitive European market. Our lead commercialized product, Binosto® for the treatment of osteoporosis, is marketed in the US as well as selected European and Asian countries.
Disclaimer: Information for investors. Please always refer to the official Prescribing Information of Binosto® containing the approved indications, contraindications, safety information and warnings in your country.
18.11.2020
EffRx Pharmaceuticals Signs Exclusive License Agreement with Dipharma SA and Launches Miglustat Dipharma in Switzerland
FREIENBACH, Switzerland – EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Dipharma SA, a Swiss specialty pharmaceutical company, developing high quality, improved medicines for rare diseases. Under the terms of the agreement, EffRx has received exclusive rights to commercialize Miglustat Dipharma in Switzerland.
Miglustat Dipharma is a generic equivalent to Actelion’s (Johnson & Johnson’s) Zavesca®1. It is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable, as well as for the treatment of progressive neurological manifestations in adult and pediatric patients with Niemann-Pick type C disease.
Gaucher disease and Niemann-Pick disease belong to a larger group of more than 50 disorders known as lysosomal storage disorders. They are inherited metabolic diseases that are characterized by an abnormal build-up of various toxic materials in the body’s cells as a result of enzyme deficiencies.
Patients with mild to moderate type 1 Gaucher disease lack an enzyme called glucocerebrosidase, which results in a glycosphingolipid called glucosylceramide building up in different parts of the body, such as the spleen, liver and bones. Miglustat Dipharma is used in patients who cannot receive the standard treatment of enzyme replacement therapy. Niemann-Pick type C is a potentially fatal disease in which glycosphingolipids build up within cells in the brain and elsewhere in the body. Miglustat Dipharma is used to treat the neurological symptoms of the disease.
The addition of Miglustat Dipharma marks another milestone for EffRx Pharmaceuticals’ growing portfolio of niche and orphan medicines in Switzerland. After having secured the rights for innovative therapies to treat conditions like cystic fibrosis and pediatric adrenal insufficiency, EffRx is thrilled to be able to launch a product which has an established place in the treatment of two major lysosomal storage disorders.
Miglustat Dipharma is reimbursed in Switzerland as of 1 November 2020.2 It provides a therapeutic alternative for patients and important cost savings for the Swiss healthcare system.
About EffRx Pharmaceuticals
EffRx Pharmaceuticals is a commercial-stage pharmaceutical company focused on the late stage development and commercialization of prescription medications for niche and orphan indications. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients.
EffRx pro-actively seeks in-licensing opportunities for Europe in niche therapeutic areas, with a primary interest for rare diseases, where EffRx has received an orphan drug designation (ODD) from the FDA for a pipeline asset.
EffRx’s go-to-market competence is proven by the development, launch and lucrative expansion of Binosto® in a highly competitive European market. Our lead commercialized product, Binosto® for the treatment of osteoporosis, is marketed in the US as well as selected European and Asian countries.
About Dipharma SA
Dipharma S.A. is a Swiss specialty pharmaceutical company, developing high quality, improved, medicines for rare diseases. Dipharma S.A. is part of a third-generation group of family-owned companies that have grown to a global presence.
With a portfolio of generic orphan products for the treatment of Phenylketonuria, Gaucher Disease, Hereditary Tyrosinemia Type 1, Urea Cycle Disorders and others, Dipharma S.A. provides improved solutions for patients affected by inborn metabolic diseases at an affordable cost and with a global reach.
For more information, please visit www.dipharma.ch
Media contact: Ms. Pamela Saredi, psaredi@effrx.com
1 Zavesca® is a registered trademark of Actelion Pharmaceuticals Ltd.
2 Reimbursed for the treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not possible.
19.08.2020
World Osteoporosis Day – WOD marked on October 20th
Countdown to World Osteoporosis Day: A digital countdown checklist is an easy way to learn good bone health basics.
WOD, marked on October 20 each year, is year-long campaign dedicated to raising global awareness of the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases.
It aims to put bone health and fracture prevention on the global health agenda and reaches out to health-care professionals, the media, policy makers, patients, and the public at large.
Get tested and treated if required:
- Could you be at risk of broken bones due to osteoporosis? Take the IOF Osteoporosis Risk Check to see whether any risk factors apply to you!
- Have you broken a bone after age 50? Without treatment, one fracture leads to another.
- Do you have a family history of broken bones? You could be at risk.
- Are you getting shorter? This could be a sign of spine fractures due to osteoporosis.
- Calcium is important for bone health. Are you getting enough of this important mineral? Find out with the IOF Calcium Calculator.
- Osteoporosis affects 1 in 3 women and 1 in 5 men aged 50+ worldwide. Don’t let it affect you! Take action for prevention.
19.08.2020
EffRx Mourns Passing of Board Member Anders Wiklund
FREIENBACH, Switzerland, 19th August 2020
The leadership of EffRx Pharmaceuticals SA is extremely saddened to announce the passing of longtime Board Member and former Chairman, Anders P. Wiklund.
Anders, a Swedish citizen, has been a board member of EffRx since its incorporation in Switzerland in 2009, and served as Chairman of EffRx between 2015 and 2016. He also acted as CEO at former EffRx Inc., USA.
“Anders will be greatly missed by the entire EffRx family. We are deeply saddened by his passing and by the loss of a friend and colleague. We are especially honored for the entrepreneurial passion towards healthcare he carried in his heart and thankful for his outstanding leadership, experience and wisdom”, said Lorenzo Bosisio, CEO of EffRx. “Anders will always remain an indelible role model in our thoughts.”
On behalf of our Board of Directors, management team and employees, we extend our deepest sympathies to Anders’ family.
About EffRx Pharmaceuticals SA
EffRx Pharmaceuticals is a commercial-stage pharmaceutical company focused on the late-stage development and commercialization of prescription medications for niche and orphan indications. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients.
18.08.2020
EffRx Pharmaceuticals SA to Showcase Binosto® at the Virtual WCO-IOF-ESCEO 2020 Congress
EffRx Pharmaceuticals SA is proud to announce that it will participate in the 20th Edition of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, starting on the 20th of August 2020. The WCO-IOF-ESCEO Congress is the world’s leading clinical conference on bone, joint and muscle health and therefore the ideal venue for EffRx to showcase its flagship product Binosto®, the only buffered soluble alendronate for the treatment of postmenopausal osteoporosis.
EffRx Pharmaceuticals SA is also pleased to inform that a study on the cost-effectiveness of Binosto® will be presented at the WCO-IOF-ESCEO Congress. The data will be presented by Professor M. Hiligsmann in an oral communication (OC40) entitled, “COST-EFFECTIVENESS OF BINOSTO (BUFFERED SOLUBLE ALENDRONATE 70 MG) EFFERVESCENT TABLET FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN ITALY.”
The authors of the cost-effectiveness study conclude that Binosto® represents a cost-effective strategy compared with generic alendronate, zoledronic acid and no treatment, and a dominant strategy compared to denosumab for the treatment of postmenopausal women with osteoporosis in Italy aged 60 years and over.
Medical professionals from around the world will be able to learn more about Binosto® and its exciting properties at the Binosto® virtual booth.
About EffRx Pharmaceuticals SA
EffRx Pharmaceuticals is a commercial-stage pharmaceutical company focused on the late-stage development and commercialization of prescription medications for niche and orphan indications. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients.
About Binosto®/Steovess®
Our lead commercialized product Binosto® is indicated for the treatment of osteoporosis and marketed in US, Europe and Asia. Binosto® (alendronate 70 mg effervescent tablets) is the first and only buffered solution for the treatment of postmenopausal osteoporosis. It reduces the risk of hip, spine, and non-spine fractures.1 The buffered solution with high acid-neutralizing capacity minimizes the risk of exposing the esophagus (in case of reflux) and the stomach to acidified alendronate.2,3 Binosto® is taken once a week as an easy-to-swallow, buffered solution with no risk of a tablet getting lodged in the esophagus. Binosto® has the potential to improve adherence to therapy4, thereby decreasing the risk of disabling fractures.
Disclaimer
Please refer to the official Binosto®/Steovess® prescribing information and approved indications, contraindications, and warnings in your country.
References:
- Black DM et al. Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4118-4124.
- Binosto Summary of Product Characteristics. 2019.
- Hodges LA et al. Modulation of gastric pH by a buffered soluble effervescent formulation: A possible means of improving gastric tolerability of alendronate. Int J Pharm 2012;432:57-62.
- Giusti A et al. Persistence with Buffered Solution of Alendronate 70mg: Prospective Observational Study. J Bone Miner Res 2018;33(S1):S174-S175.
25.03.2020
COVID-19 and Osteoporosis
Stay safe and well informed. The IOF provides some helpful information for older adults and people with osteoporosis.
23.03.2020
EffRx Pharmaceuticals Statement on COVID-19
The globe has literally gone into quarantine due to the COVID-19 outbreak. This is an unprecedented crisis situation in terms of breadth and scale, from a global health, social and economic standpoint.
While committed to keep our core activities unaffected, EffRx has implemented measures aimed at guaranteeing business operation continuity, with particular focus on the supply of Binosto® to our customers. EffRx has engaged with its suppliers and clients to ensure continuity of the business and will continue to monitor the situation as it evolves with the aim to minimize the impact of this crisis on our business.
EffRx has further taken internal measures to reduce the contamination risk for employees and business partners. The health of our staff and partners is our number one priority. The entire staff is working remotely from home with effective equipment & systems. We have also cancelled all travels, replaced face-to-face meetings/trainings by virtual meetings and are pursuing digital collaboration with all our stakeholders.
We thank for your loyalty, flexibility and understanding for the unforeseen consequences of this global pandemic. We are in this together.
Wishing you all good health.
EffRx Pharmaceuticals
Lorenzo Bosisio
CEO
19.02.2020
29 February 2020 will be the 13th international Rare Disease Day coordinated by EURORDIS
Rare Disease Day takes place on the last day of February each year. The main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients’ lives.
Building awareness of rare diseases is so important because 1 in 20 people will live with a rare disease at some point in their life. Despite this, there is no cure for the majority of rare diseases and many go undiagnosed. Rare Disease Day improves knowledge amongst the general public of rare diseases while encouraging researchers and decision makers to address the needs of those living with rare diseases.
Learn more about Rare Disease Day here.
08.01.2020
EffRx Pharmaceuticals Attending the 38th Annual J.P. Morgan Healthcare Conference from January 13-16, 2020 in San Francisco
The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.
07.11.2019
Meet the EffRx Team at the 25th Annual BIO-Europe International Conference from November 11-13, 2019 in Hamburg
EffRx will be attending Europe’s largest life science partnering conference, BIO-Europe, which offers countless opportunities to engage with global life science partners. This year´s BIO-Europe partnering event will again draw over 4,000 industry attendees from over 60 countries, representing more than 2,000 companies for three days of high-level networking.
To set up a meeting, please contact us via the partnering platform or at info@effrx.com.
11.07.2019
EffRx to Attend the Medical Meeting: Bisphosphonates2019, Celebrating 50 Years from 15-17th July 2019 in Sheffield, UK
EffRx Pharmaceuticals SA is proud to announce that it will attend the upcoming medical meeting bisphosphonates2019 – Celebrating 50 years, taking place 15-17th of July 2019 in Sheffield, UK. The year 2019 marks 50 years since the first publication on the biological effects of the bisphosphonates. The meeting which focuses 100% on bisphosphonates will review developments over the past 50 years, discuss our current understanding and look at what the future may hold.
EffRx Pharmaceuticals SA is also pleased to inform that new safety data on Binosto® will be presented at the Bisphosphonates2019 medical meeting. The data will be presented as a poster and oral snap presentation titled “Upper Gastrointestinal Safety with the Buffered Solution of Alendronate 70 mg: 6 Years of Post-Marketing Experience” authored by B. Cortet, P. Fardellone, L. Zakin, E. Fink Eriksen on Monday, 15th of July 2019, at 12:55 pm (poster #40).
The authors of the new Binosto® safety data conclude that Binosto® is associated with a lower frequency of upper gastrointestinal adverse reactions than reported for alendronate tablets and that it is a well-tolerated oral bisphosphonate for the management of osteoporosis.
“The safety data, after 6 years of post-marketing experience, reinforce that Binosto® is a well-tolerated oral bisphosphonate for the management of osteoporosis,” says Dr Lorraine Zakin, Medical Affairs Director at EffRx Pharmaceuticals.
EffRx looks forward to seeing you at the Bisphosphonates2019 in Sheffield!
About EffRx Pharmaceuticals SA
EffRx Pharmaceuticals SA is a commercial-stage functionally integrated pharmaceutical company, based in Switzerland, that develops and commercializes niche & orphan medicines in Europe. EffRx aims to be the preferred accelerator for late clinical & regulatory development, approval, valorization of niche & orphan medicines in Europe and Switzerland.
About Binosto®/Steovess®
Our lead commercialized product, Binosto® is indicated for the treatment of osteoporosis. Binosto® (alendronate 70 mg effervescent tablets) is the first and only buffered solution for the treatment of postmenopausal osteoporosis. It reduces the risk of hip, spine, and non-spine fractures.1 The buffered solution with high acid-neutralizing capacity minimizes the risk of exposing the esophagus (in case of reflux) and the stomach to acidified alendronate.2,3 Binosto® is taken once a week as an easy-to-swallow, buffered solution with no risk of a tablet getting lodged in the esophagus. Binosto® has the potential to improve adherence to therapy4, thereby decreasing the risk of disabling fractures.
Disclaimer
Statements made here are according the approved Binosto Summary of Product Characteristics in Europe. Please refer to the Binosto®/Steovess® prescribing information and approved indications, contraindications, and warnings in your country.
References:
- Black DM et al. Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4118-4124.
- Binosto Summary of Product Characteristics. 2017.
- Hodges LA et al. Modulation of gastric pH by a buffered soluble effervescent formulation: A possible means of improving gastric tolerability of alendronate. Int J Pharm 2012;432:57-62.
- Giusti A et al. Persistence with the buffered solution of alendronate 70 mg: prospective observational study. Osteoporos Int 2018;29(S1):S431.
Media Contact: Pamela Saredi, psaredi@effrx.com
14.06.2016
Meet EffRx Pharmaceuticals at the BIO International Convention from June 3-6, 2019 in Philadelphia
BIO International Convention is back in Philidelphia, June 3-6, to celebrate history-making innovation and EffRx will take part. This is the only event where one can access the global biotech and pharma community via Partnering and network with 16,000+ attendees from 67 countries.
09.04.2019
Binosto® Booth a Success at the WCO-IOF-ESCEO Congress in Paris
EffRx would like to thank everyone who helped make the Binosto® booth a success at the 19th Edition of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. With more than 4,000 delegates, the WCO-IOF-ESCEO Congress was an optimal platform for showcasing our lead product Binosto®.
21.02.2019
Rare Disease Day is on February 28, 2019 – Help Raise Awareness
The main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients’ lives.
The campaign targets primarily the general public and also seeks to raise awareness amongst policy makers, public authorities, industry representatives, researchers, health professionals and anyone who has a genuine interest in rare diseases.
Rare Disease Day was launched by EURORDIS-Rare Diseases Europe and its Council of National Alliances in 2008.
25.10.2018
Meet the EffRx Team at the 24rd Annual BIO-Europe International Conference from 5-7 November 2018 in Copenhagen
The 24th annual BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry. Delegates from all parts of the biotechnology value chain come to BIO-Europe to quickly identify, engage and enter into strategic relationships that drive their businesses successfully forward. Investment and collaboration opportunities developed in prior BIO-Europe conferences have produced many highly successful business partnerships.
This year´s BIO-Europe partnering event will again draw over 4,000 industry attendees from over 60 countries, representing more than 2,100 companies for three days of high level networking.
To set up a meeting, please contact us via the partnering platform or at info@effrx.com.
18.10.2018
World Osteoporosis Day – WOD, on October 20th: Help Spread the Word
World Osteoporosis Day – WOD, marked on October 20th each year, is year-long campaign dedicated to raising global awareness of the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal disease.
It aims to put bone health and fracture prevention on the global health agenda and reaches out to health-care professionals, the media, policy makers, patients, and the public at large.
Some Facts About Osteoporosis:
- By 2050, the worldwide incidence of hip fracture in men is projected to increase by 310% and by 240% in women.
- Osteoporosis accounts for more days in the hospital than breast cancer, heart attack, diabetes & other diseases.
- Loss of independence after a hip fracture, approximately 60% require assistance a year later and 20% will require long-term nursing care.
- Fracture risk up to 27% higher than prostate cancer risk.
- Aged 50+ 1/3 women 1/5 men: will suffer an osteoporotic fracture worldwide.
Knowing your risk factors
Take the IOF One-Minute Osteoporosis Risk Test to find out whether you may have specific factors which place you at higher risk of osteoporosis and fractures.
www.iofbonehealth.org/iof-one-minute-osteoporosis-risk-test
EffRx commitment to bone health:
Although a small-scale company, EffRx’s employees have made personal efforts to make some noise on behalf of the WOD. Each employee has asked relatives, friends and acquaintances throughout October to support the IOF Global Patient Charter (https://www.iofbonehealth.org/iof-global-patient-charter)
Additionally, in honor of World Osteoporosis Day, EffRx organized a company bone-healthy-brunch on October 16th. Although bone-healthy nutrition is important – particularly to build maximum peak bone mass in adolescents -, drug therapies are critical for fracture prevention in people at high risk of fracture. Today, there are many proven and effective treatments which have been shown to reduce the risk of osteoporotic fracture by between 30–50%.
29.05.2018
Meet EffRx at the BIO International Convention from June 4-7, 2018 in Boston
BIO International Convention is back in Boston, June 4-7, to celebrate history-making innovation and EffRx will take part. This is the only event where one can access the global biotech and pharma community via Partnering and network with 16,000+ attendees from 74 countries.
11.04.2018
EffRx to Showcase Binosto® at WCO-IOF-ESCEO 2018 in Krakow, Poland
EffRx Pharmaceuticals SA is proud to announce that it will participate in the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases in Krakow, Poland, from 19 to 22 April 2018. The WCO-IOF-ESCEO Congress is the world’s leading clinical conference on bone, joint and muscle health and therefore the ideal venue for EffRx to showcase its flagship product Binosto®, the only buffered soluble alendronate for the treatment of postmenopausal osteoporosis. Learn more
30.01.2018
European market-entry strategy for biopharma companies
The European pharmaceutical market offers many opportunities for U.S. biopharmaceutical companies. An early engagement as well as a visceral understanding of the heterogeneity of the European market are key to succeed. Partnering with EffRx Pharmaceuticals, a commercial-stage pharmaceutical company offers various advantages. Because of its diversity and non-bureaucratic access to a talented workforce, EffRx an ideal partner to kick off your international go-to-market strategy.
For the entire article please go to the Greater Zürich Area.
26.10.2017
Meet the EffRx Team at the 23rd Annual BIO-Europe International Conference from 6-8 November 2017 in Berlin
The 23rd Annual BIO-Europe International Conference is the “must-attend” event and Europe’s largest life science partnering conference. And EffRx will be there.
The conference brings together hundreds of the world’s most innovative leaders across biotech, finance and pharma for high-level networking, pre-scheduled partnering meetings, strategic panel discussions and more.
To arrange for a meeting, please contact us via the BIO-Europe partnering platform.
17.06.2017
Meet EffRx Pharmaceuticals at the BIO International Convention in San Diego, 19-22. June 2017
EffRx will participate in the parterning forum at the BIO International Convention (BIO). BIO attracts 16,000 biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. They bring together a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.
07.03.2017
Binosto data to be presented at the WCO-IOF-ESCEO Congress in Florence
EffRx Pharmaceuticals SA is proud to announce that it will participate in the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases in Florence, Italy, from 23 to 26 March 2017. The WCO-IOF-ESCEO Congress, as it is also known, is the world’s leading clinical conference on bone, joint and muscle health and therefore the ideal venue for EffRx to showcase its flagship product Binosto, the world’s first and only buffered soluble alendronate for the treatment of postmenopausal osteoporosis. Medical professionals from around the world will be able to learn more about Binosto and its exciting properties at the Binosto booth in the exhibition area (booth #21).
EffRx Pharmaceuticals SA is equally thrilled to inform that it will present the latest safety data on Binosto at the WCO-IOF-ESCEO Congress. The data will be presented in the poster area on 24 March 2017, from 14:00 to 15:00 (poster #589).
Please join EffRx at the WCO-IOF-ESCEO Congress in Florence!
15.02.2017
Bone markers as screening strategy for patient adherence to osteoporosis medications
IOF-ECTS Position Paper provides recommendations for the screening of adherence to oral bisphosphonates; proposes assessment using PINP and CTX bone turnover markers (BTMs) at baseline and after three months.
Oral bisphosphonates are common first line treatments for osteoporosis. However, approximately half of patients who begin osteoporosis treatment do not follow their prescribed treatment and/or discontinue treatment within a year. Identifying low adherence to medication – a problem commonly seen with many chronic diseases – is a critical issue as it jeopardizes the efficacy of treatment, leaving osteoporosis patients unprotected against fractures.
For the complete news story, visit the International Osteoporosis Foundation online.
21.12.2016
EffRx Pharmaceuticals Attending the 35th Annual J.P. Morgan Healthcare Conference
EffRx Pharmaceuticals will be attending the 35th Annual J.P. Morgan Heathcare Conference to take place from January 9-12, 2017 at the Westin St. Francis Hotel in San Francisco, California. To arrange for a meeting, please contact us at info@effrx.com
25.10.2016
Meet the EffRx Team at BIO-Europe 2016 in Cologne, Germany on Nov. 7-9, 2016
EffRx Pharmaceuticals will be attending the 22nd Annual International Partnering Conference in Cologne, Germany. BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry. To arrange for a meeting with us, please contact us via the BIO-Europe partnering platform or at info@effrx.com
14.06.2016
EffRx Announces Changes in the Composition of the Board of Directors
Freienbach, June 14th, 2016 — EffRx Pharmaceuticals SA, a specialty pharmaceutical company focused on the development of novel therapeutic entities for orphan and specialty indications, today announced the appointment of Dr. Jonas Ekblom as Chairman and Dr. Alcide Barberis as Member of the Board of Directors.
“I feel elated to join the Board of this exciting company and I look forward to working with the Management team and the Board of Directors as we progress EffRx into its next phase of consolidation, maturation and growth,” commented Dr. Jonas Ekblom, Chairman.
Dr. Ekblom and Dr. Barberis will be replacing Mr. Oscar Ahlgren, Mr. Carl-Gustaf Johansson and Mr. Thomas Mårtensson who have stepped down from their current role as Directors. During their tenure they have successfully managed the transition of EffRx to become an integrated pharmaceutical company with its flagship program, Binosto®, being now commercialized in 10 key countries across Europe, Asia and America. Mr. Anders Wiklund will continue to serve as a Board Director and with his accomplished industry experience will ensure a smooth transition within the Board.
Dr. Jonas Ekblom brings over 20 years of experience from the life science sector, with a focus in pharmacology and drug development. He has managed R&D programs in in several therapeutic areas. Dr. Ekblom has business experience from US, EU and Asia.
Dr. Alcide Barberis is a biotech entrepreneur and manager with over 20 years management experience in the biotechnology industry and scientific experience in the private and public research sectors.